Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 6/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.53 |
| ▸ | CDK2 | P24941 | 4/20 | 0.53 |
| ▸ | CDK9 | P50750 | 4/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.50 |
| ▸ | PRKACA | P17612 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | CLK1 | P49759 | 3/20 | 0.46 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446754 | 0.81 | NPC1 (0.41) | HSP90AA1KMOKDM4ENPC1RAB9A | |
| SCHEMBL1914955 | 0.80 | HSP90AA1 (0.59) | CDK5CDK5R1CDK2CDK9CCNT1 | |
| SCHEMBL10915242 | 0.79 | CDK5 (0.53) | CDK5CDK5R1CDK2CDK9CCNT1 | |
| SCHEMBL21908761 | 0.79 | CDK5 (0.53) | CDK5CDK5R1CDK2CDK9CCNT1 | |
| SCHEMBL29889857 | 0.79 | CDK5 (0.53) | CDK5CDK5R1CDK2CDK9CCNT1 | |
| SCHEMBL28295771 | 0.79 | ASIC3 (0.44) | CDK2HSP90AA1CDC7KDM4EALDH1A1 | |
| SCHEMBL1265327 | 0.78 | DPP4 (0.40) | CDK5CDK5R1CDK2CDK9CCNT1 | |
| SCHEMBL30046927 | 0.76 | HSP90AA1 (0.60) | CDK5CDK5R1CDK2CDK9CCNT1 | |
| SCHEMBL18130895 | 0.76 | HSP90AA1 (0.60) | CDK5CDK5R1CDK2CDK9CCNT1 | |
| SCHEMBL6530231 | 0.75 | FGFR2 (0.52) | CDK2CDC7KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2818170-B1 | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | AMGEN INC (US) | 2018-12-05 | — | — | EP | disclosed |
| US-10053452-B2 | Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof | AMGEN INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20160304504-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF | AMGEN INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304504-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF | AMGEN INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304504-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF | AMGEN INC. | 2016-10-20 | — | — | US | disclosed |
| EP-3077392-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL) - 2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1 -PHTHALAZINAMINE PHARMACEUTICALLY ACCEPTABLE SALTS AND USES THEREOF | Amgen Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160213669-A1 | USE OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1-PHTHALAZINAMINE IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-07-28 | — | — | US | disclosed |
| US-20160213669-A1 | USE OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1-PHTHALAZINAMINE IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-07-28 | — | — | US | disclosed |
| US-20160213669-A1 | USE OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1-PHTHALAZINAMINE IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-07-28 | — | — | US | disclosed |
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20070213325-A1 | Multi-cyclic compound and method of use | AMGEN INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007100646-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1751136-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005113494-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | CDK5 49/4885CDK5R1 51/4885CDK2 6/4885 |
| US-20160213669-A1 | USE OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1-PHTHALAZINAMINE IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF CANCER | HDAC4, HDAC9, HDAC5 | CDK5 346/4885CDK5R1 480/4885CDK2 269/4885 |
| US-20070213325-A1 | Multi-cyclic compound and method of use | TIE1, CDK1, CCNB1 | CDK5 55/4885CDK5R1 89/4885CDK2 4/4885 |
| US-20160304504-A1 | CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF | BCL9, NPM1, MLLT3 | CDK5 902/4885CDK5R1 2111/4885CDK2 461/4885 |
| US-10053452-B2 | Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof | BCL9, NPM1, MLLT3 | CDK5 902/4885CDK5R1 2111/4885CDK2 461/4885 |
| US-20060009453-A1 | Protein kinase modulators and method of use | PHKG1, PRKCH, BMP2K | CDK5 9/4885CDK5R1 36/4885CDK2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.